PDCD1 and melanoma: Immunotherapy such as targeting PD-1 pathway has improved overall survival months of several patients with metastatic cancers, including melanoma, head and neck cancer, renal cell carcinoma, non-small cell lung cancer (NSCLC), and colon cancer.